Clinical Trial Search

Primary: Concentration of Serum Total 25-hydroxyvitamin D Attained at or Above 50 ng/mL at Visit 3 (Day 14). — 51; 10 Participants

Primary: Monocular logMAR Visual Acuity — 0.033; 0.038 logMAR

Primary: Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination — 39.2; 45.9; 33.0; 27.5 Percentage of participants

Primary: Mean Change From Baseline Psoriasis Area and Severity Index (PASI) at Week-24 After Treatment With Guselkumab. — 61.8 percent change from baseline PASI

Primary: Cohorts 1a and 1b: Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) for 7 Days After Vaccination 1 in the Primary Regimen — 50; 50; 57…

Primary: Number of Participants With Dose-Limiting Toxicity (DLT) in Phase 1 — 0; 1; 1; 3 Participants

Primary: Mean Cortisol (CRT) During Trier Social Stress Test (TSST) — 19.17; 16.87; 15.71; 13.89 pg/mL — p=0.37

Primary: Absolute Change in Intrahepatic Lipid Content, by 1H-MRS — -6.6; 3.6 Mean absolute percentage change

Primary: Change From Baseline to 4 Hours in Sputum Percent Neutrophils — -2.62; 5.45 percent neutrophils — p=0.24

Primary: Identify a Feasible Schedule of Vaccination Relative to SoC Neoadjuvant Chemotherapy When the Chemovax Are Administered Concurrently. — 3; 2; 4; 2 Participants

Primary: Change in Epworth Sleepiness Scale (ESS) Score — 5.0; 4.4 score on a scale

Primary: Groups 1, 2, 3, 4, 5 and 6: Number of Participants With Solicited Local Adverse Events (AEs) at 7 Days Post-dose 1 — 13; 16; 17; 11 Participants

Primary: Number of Participants With Adverse Events (AEs) — 4 Participants

Primary: Concentration of Angiotensin Converting Enzyme (ACE 1) — 4043.15; 4028.17; 3836.31; 3305.21 ng/mL

Primary: AUC From Day 90 To Day 180, Based on Percent Change From Baseline in 24-Hour Uox — 3507.4; -1664.4 Percent change in 24-hour Uox AUC — p=<0.0001